



PRESS RELEASE

01 June 2026 11:00:00 CEST

AcouSort to present and exhibit at the CYTO conference in West Palm Beach in June

AcouSort AB today announced that the company will present a poster showing the benefits of using its technology to improve sample quality before flow cytometry analysis at the annual CYTO conference at the Palm Beach County Convention Center in West Palm Beach, FL, June 6 - 10, 2026. AcouSort will also exhibit at the conference.

“The conference is an important event for AcouSort giving us the opportunity to meet with leading manufactures of flow cytometers, as well as with advanced users looking for novel solutions to improve sample quality,” said AcouSort’s Commercial Director Dr. Agnes Michanek.

The poster presentation focuses on the benefits of using AcouSort’s technology improving sample quality before cytometry analysis, evaluating sample purity and cell health in samples processed using the company’s technology compared with standard techniques like centrifugation.

AcouSort will also participate as an exhibitor at the conference (Booth #229).

CYTO 2026, the 39th annual Congress of the International Society for the Advancement of Cytometry, is the premier international conference on the many facets of cytometry science and engineering. Guided by this year’s theme, “Cytometry: The Next Wave”, the meeting will showcase groundbreaking innovations and emerging directions shaping the field.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.